IL-17A and IL-17F in Inflammatory Diseases
Psoriasis
Chronic activation against targeted host cells, the proinflammatory capacity, and dysregulation of IL-17A result in psoriatic skin lesions and pathogenic inflammation in patients with psoriasis.12 Treatment approaches that combine neutralization of IL-17A and IL-17F, also implicated in the inflammatory process, show promise in providing greater depth of clinical response in some autoimmune diseases.5
Psoriatic Arthritis
Therapies that block IL-17A have shown efficacy in the treatment of psoriatic arthritis.12 Recent research shows promise in a combined neutralization of both IL-17A and IL-17F in patients with autoimmune diseases, including psoriatic arthritis.5
Rheumatoid Arthritis
While the presence of IL-17A in the joints of patients with rheumatoid arthritis suggest the cytokine as a therapeutic target for treatment, clinical studies have shown limited efficacy.12,13 The role of IL-17F in rheumatoid arthritis remains unclear.13
Spondyloarthritis
Findings from a study that investigated rapamycin for the treatment of spondyloarthritis showed efficacy as the incidence and severity of spondylitis and arthritis were reduced. Both IL-17A and IL-17F were shown to play essential pathogenic roles in the proinflammatory pathways involved with this disease.14
Asthma
Airway tissues taken from patients with severe asthma showed that both IL-17A and IL-17F play key roles in the pathogenesis of asthma with notably strong associations with severe disease.15
Crohn Disease
In patients with Crohn disease, clinical trials that introduced neutralizing agents targeting IL-17 and IL-17RA resulted in limited efficacy and sometimes worsened the disease.12,16 Other studies that targeted IL-17 secretion pathways showed efficacy.16
Multiple Sclerosis
Serum samples taken from patients with multiple sclerosis contained significantly higher levels of IL-17 than those of healthy patients, with levels found to correlate with disease activity confirmed through magnetic resonance imaging.16
Alzheimer Disease
The primary involvement of IL-17 in Alzheimer disease involves the recruitment and function of neutrophils in the CNS. In vitro study results suggest that the proinflammatory capacity of IL-17 might involve promoting autophagy in the brain’s neurons, resulting in the neurodegeneration that occurs with disease progression.16
Advertisement
Current Issue
October 2024
Volume 32
Issue 7
Advertisement
CME Opportunities
Advertisement
Advertisement
